<br>        Inclusion Criteria:<br><br>          -  Males or females between 18 and 65 years of age scheduled for low- or moderate-risk<br>             surgical procedure requiring tracheal intubation<br><br>          -  Female patients must not be of child-bearing potential.  Females must meet one of the<br>             following criteria:<br><br>               -  Be postmenopausal;<br><br>               -  Have undergone prior tubal ligation or hysterectomy; or<br><br>               -  Be scheduled for hysterectomy as the surgical procedure for this  study.<br><br>          -  American Society of Anesthesiologists (ASA) Physical Status Classification 1 or 2<br><br>          -  Weight within 30% of ideal body weight<br><br>          -  Able to read and to comprehend information about the study design and procedure;<br>             willingness to participate in this study as evidenced by a signed and dated written<br>             Informed Consent form<br><br>          -  In good physical and mental health as determined by the procedures/evaluations<br>             (completed within 14 days prior to the Induction Phase [scheduled surgical<br>             procedure])<br><br>        Exclusion Criteria:<br><br>        A patient will not be eligible for inclusion in this study if any of the following<br>        criteria are met:<br><br>          -  Evidence of clinically significant cardiovascular, neuromuscular, neurological,<br>             psychiatric, renal, hepatic or pulmonary disease (including asthma), or impairment of<br>             function (as judged by the investigator)<br><br>          -  Personal or family history of unusual sensitivity to NMBs or other agents used in<br>             surgical anesthesia<br><br>          -  Anatomical characteristics recognized as being associated with difficult intubation<br>             conditions, even in the presence of complete jaw and vocal cord relaxation<br><br>          -  History or evidence of vocal cord polyps and/or paralysis<br><br>          -  History or evidence of narrow angle glaucoma<br><br>          -  Personal or family history of malignant hyperthermia<br><br>          -  History of major thermal injury that required hospitalization<br><br>          -  Presence of genetically determined disorders of plasma cholinesterase, as determined<br>             by medical history<br><br>          -  History or current evidence of abuse of any drug substance, licit or illicit<br>             (including alcohol)<br><br>          -  Exposure to any of the following agents within 48 hours prior to the Induction Phase<br>             of the study, or, if expected to be administered within the first 15 minutes after<br>             administration of study treatment: antibiotics (except penicillins, cephalosporins,<br>             and tetracyclines), i.v. lidocaine (except i.v. lidocaine administered in conjunction<br>             with propofol to reduce local irritation), quinidine, trimetaphan, or dexamethasone.<br><br>          -  Exposure to any of the following agents within 7 days prior to the Induction Phase of<br>             the study: tricyclic antidepressants, phenothiazines, anticonvulsants, antihistamines<br>             (H1 - or H2 - receptor antagonists), antihypertensives, antiarrhythmics (including<br>             procainamide), beta blockers (including propranolol, calcium channel blockers),<br>             diuretics (including furosemide, thiazides, mannitol, and acetazolamide), potent<br>             narcotics (including, but not limited to, oxycodone, methadone, morphine,<br>             buprenorphine, hydromorphone), and magnesium or lithium salts.  Note: weak opioids<br>             including, but not limited to, propoxyphene, tramadol, hydrocodone, codeine,<br>             meperidine, and tilidine are not reasons for exclusion provided no changes in daily<br>             dosage have occurred within 3 days prior to the Induction Phase of the study.<br><br>          -  Exposure to monoamine oxidase inhibitors within 14 days prior to the Induction Phase<br>             of the study.<br><br>          -  Exposure to anticholinesterase or cholinomimetic agents within 30 days prior to the<br>             Induction Phase<br><br>          -  Previous entry into this or any other study of gantacurium chloride for injection, or<br>             participation in any other investigational drug, biologic, or medical device study<br>             within 30  days prior to the Induction Phase<br><br>          -  Pregnant (positive pregnancy test during Screening) or breastfeeding/donating breast<br>             milk<br><br>          -  Any other condition that, in the opinion of the investigator, would jeopardize the<br>             safety or rights of a subject participating in the trial or would render the subject<br>             unable to comply with the protocol<br>